S-Biomedics has completed dosing 12 patients in the phase 1/2a clinical trial of its Parkinson disease treatment TED-A9. The treatment uses a mechanism involving transplantation of embryonic stem cell-derived dopaminergic neurons, with safety evaluated in low- and high-dose group
2026-05-14
Immuno-oncology drug developer Eutilex recorded an operating loss of 2.6 billion won in the first quarter and entered rehabilitation proceedings, putting it at risk of delisting. As a result, clinical development of four oncology pipelines, including the GPC3-CAR-T therapy EU307,
2026-05-14
Amicogen has begun developing an improved hyaluronidase for subcutaneous (SC) formulations in a market valued at $12 billion and has completed a patent application. The enzyme, which has enhanced activity and stability at neutral pH, is expected to complete cell line development
2026-05-14
EuBiologics has signed a 155 billion won ($106.93 million) supply agreement with UNICEF for 72.1 million doses of its cholera vaccine Euvichol. The long-term agreement (LTA) covers supplies through 2026 and also includes Euvichol-S, an improved version of the vaccine that increas
2026-05-14
ANXA11 has been identified as a key inhibitory molecule that blocks muscle regeneration in patients with Duchenne muscular dystrophy (DMD), with its expression markedly increased in MYH3⁺ regenerating myofibers. ANXA11 disrupts the mTOR signaling pathway and acts as a “brake” tha
2026-05-14
iNtRON Biotechnology has burned a total of 2.3 million treasury shares as part of efforts to enhance shareholder value. The company retired 1.57 million shares on Feb. 24 and 720,000 shares on April 10 through profit-based cancellation. The cancellations were carried out within t
2026-05-14
Osteonic’s biomaterials sales reached 6.6 billion won in the first quarter, surpassing metal materials for the first time and bringing total sales to 12.9 billion won. Sports Medicine products accounted for 5.6 billion won, while exports to the Americas surged 169%, driving growt
2026-05-14
Komipharm obtained marketing authorization for export of its African swine fever (ASF) vaccine, ProVac ASF, in April. The company is currently conducting a final field trial in the Philippines and plans to begin full-scale exports after the trial ends in July. Meanwhile, its anti
2026-05-14
Genexine launched its long-acting anemia treatment Efesa (GX-E4) in Cambodia in January 2026, achieving its second commercialization following Indonesia. Efesa is a treatment for anemia associated with chronic kidney disease administered once or twice monthly using Genexine’s hyF
2026-05-14
HansBiomed posted KRW 6.5 billion in operating profit for the first half, swinging to a profit, and began developing three injectable products to support tendons and ligaments. The pipeline consists of human tissue products, first-generation products with an anesthetic additive,
2026-05-14
